Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2.

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to a global health crisis with millions of cases and deaths.
• Vaccination is a critical strategy for controlling the pandemic and preventing severe outcomes.
• There is a need for advanced vaccine platforms, such as multi-epitope vaccines, to enhance immune responses against SARS-CoV-2.

Purpose of the Study:

• To design and develop a next-generation multi-epitope vaccine for SARS-CoV-2 utilizing T cell epitopes.
• To assess the immunogenicity and immune response profile of the developed vaccine prototype in a preclinical mouse model.

Main Methods:

• Immunoinformatic approaches were employed to select SARS-CoV-2 T cell epitopes with high MHC binding affinity.
• A multi-epitope vaccine prototype was synthesized, incorporating eleven selected peptide binders from SARS-CoV-2 proteins (E, M, S, N).
• Immunogenicity was evaluated in humanized-ACE2 transgenic mice using in vitro, in vivo, and ex vivo immunoassays, including lymphocyte profiling and cytokine analysis (IL-4, IFN-γ).

Main Results:

• Eleven SARS-CoV-2 peptide epitopes were synthesized and formulated into a multi-epitope vaccine prototype.
• Vaccination in mice induced significant T cell responses, characterized by the production of IL-4 and IFN-γ.
• The vaccine remodeled lymphocyte profiles and elicited a weak humoral response.

Conclusions:

• The developed multi-epitope vaccine prototype is immunogenic in a preclinical mouse model.
• This study provides a foundation for the construction of a potentially effective human vaccine against SARS-CoV-2.